Acacia Research (NASDAQ:ACTG – Get Free Report) issued its quarterly earnings results on Wednesday. The business services provider reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.22, FiscalAI reports. Acacia Research had a negative net margin of 5.39% and a positive return on equity of 0.44%. The company had revenue of $114.56 million during the quarter, compared to analyst estimates of $49.50 million.
Here are the key takeaways from Acacia Research’s conference call:
- Q2 results were strong, with revenue of $114.6 million, total company adjusted EBITDA of $17.3 million, and adjusted net income of $12.8 million, or $0.13 per diluted share.
- Acacia ended the quarter with $334.6 million in cash, securities, and loans receivable and no parent-company debt, providing flexibility for acquisitions and investment in existing businesses. Management said its acquisition pipeline is active, particularly for bilateral and distressed opportunities.
- Benchmark delivered record revenue of $20.5 million, $9.8 million of adjusted EBITDA, and $6.5 million of free cash flow; management is evaluating additional wells and expects future drilling economics to be similar to the Cherokee development.
- The intellectual property platform generated approximately $60.6 million in licensing revenue, primarily from a Wi-Fi 6 settlement, but management cautioned that licensing revenue is episodic and is reduced by payments to counsel, inventors, and partners; settlement cash was received after quarter-end.
- Acacia fully wrote down its MalinJ1 investment following liquidity problems at Mycovia, although it is exploring a transaction that could provide direct ownership in Mycovia; any recovery depends on financing and uncertain FDA milestones for VIVJOA.
Acacia Research Trading Up 2.9%
NASDAQ:ACTG opened at $4.67 on Friday. Acacia Research has a 52 week low of $3.13 and a 52 week high of $5.27. The stock has a market cap of $451.07 million, a price-to-earnings ratio of -31.13 and a beta of 0.45. The company’s 50 day moving average price is $4.61 and its 200-day moving average price is $4.56. The company has a quick ratio of 8.09, a current ratio of 8.56 and a debt-to-equity ratio of 0.10.
Hedge Funds Weigh In On Acacia Research
Analyst Upgrades and Downgrades
Separately, Weiss Ratings downgraded shares of Acacia Research from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $6.00.
Read Our Latest Stock Report on Acacia Research
About Acacia Research
Acacia Research Corporation is a publicly traded patent licensing company based in New York City. The firm specializes in acquiring patented technologies through a network of wholly owned subsidiaries and seeking licensing agreements or settlements with companies that utilize those technologies. Since its founding in 1993, Acacia has built a business model centered on identifying innovative inventions and monetizing them through patent enforcement and strategic partnerships.
The company’s activities span a broad range of technology sectors, including life sciences, medical devices, software, telecommunications and consumer electronics.
Further Reading
- Five stocks we like better than Acacia Research
- Western Digital Stock Falls 12% Despite Beating Earnings Estimates
- One Comment on CVS’s Earnings Call Sent the Stock Tumbling
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
Receive News & Ratings for Acacia Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acacia Research and related companies with MarketBeat.com's FREE daily email newsletter.
